St. Jude Medical may have snagged a CE mark for its next-gen EnligHTN IV renal denervation system, but a U.S. clinical trial for the device has come to a screeching halt. That means Medtronic is poised to take a bigger lead as a result.
Edwards Lifesciences' days of market dominance are numbered, and with Medtronic impending on its U.S. monopoly and Boston Scientific soon to enter the crowded European space, the California devicemaker is less than optimistic about 2014 sales.
Medtronic is touting stellar 7-year postmarketing patient results for one of its key artificial disc implants designed to treat degenerative spinal conditions. Researchers presented the data at a major conference--a shot of good news for the Minnesota company's struggling spinal division.
Medtronic announced Thursday it has approval in the EU and Australia to market its new system for renal denervation to treat uncontrolled hypertension.
Medtronic's new surgical training facility is open for business in Jacksonville, FL. The Memphis Business Journal reported that the $14 million, 17,000-square-foot operation will train surgeons in spinal, cranial, and ear, nose and throat procedures.
A stealthy Silicon Valley medical device firm has raised $3.8 million and may be aiming to do for neurovascular diseases what one of its founders helped do for high blood pressure.
Medtronic CEO Omar Ishrak said the 2.3% device tax will cost his company as much as an extra $180 million a year. But he insisted that day-to-day business takes precedence over focusing on whether the tax can be repealed, even as industry leaders continue to push to revoke the assessment.
Medtronic is touting some positive early data on a stent graft that could expand the patient population for surgery-free endovascular repair, taking advantage of a speedy new FDA pathway set aside for innovative devices.
Medtronic's struggling spinal division is the sole black mark on an otherwise stellar fiscal 2014 second quarter. But every other division reported gains.
A massive study involving next-generation Medtronic devices shows their evolving capacity to do more than just regulate heartbeats; they may also help slow the advance of permanent atrial fibrillation and reduce hospitalization rates, researchers believe.